CASE REPORT article
Front. Med.
Sec. Dermatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1615108
Successful treatment of pityriasis lichenoides et varioliformis acuta with Stapokibart: A case report
Provisionally accepted
- 1Guizhou University of Traditional Chinese Medicine, Guiyang, China
- 2The First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Pityriasis lichenoides et varioliformis acuta (PLEVA) is a relatively rare inflammatory skin disorder encountered in clinical practice. Stapokibart is a humanized monoclonal antibody drug targeting the interleukin receptor subunit α (IL-4Rα), and is primarily used for the treatment of atopic dermatitis.Currently, owing to the rarity of PLEVA in clinical practice, there have been no reports on the use of Stapokibart in its treatment. This article presents a case in which stapokibart was used to treat a patient with acute acneiform lichenoid pityriasis, demonstrating its clinical efficacy. Following treatment with biological agents, the patient's rash completely resolved, and their quality of life significantly improved, without any adverse reactions. This case provides a valuable reference for the clinical treatment of PLEVA.
Keywords: Stapokibart, Pityriasis lichenoides et varioliformis acuta, inflammatory skin disorder, Immunomodulation, case report
Received: 20 Apr 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Shi, He and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Aijuan He, The First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.